| Title： | Guideline for diagnosis and treatment of hepatocellular carcinoma with bile duct tumor thrombus in China(2024) |
| Edition： | Updated |
| Classification： | Standard guideline |
| Field： | Diagnosis and Treatment |
| Countries and regions： | China |
| Guidelines users： | Clinicians, technicians and related teaching and research staff engaged in liver cancer related work in hospitals of all levels |
| Evidence classification method： | Ia Evidences are originated from the meta-analysis results of various RCTs Ib Evidences are originated from the results of at least one well-designed RCT IIa Evidences are originated from the results of at least one well-designed perspective non-RCT IIb Evidences are originated from the results of at least one well-designed interventional clinical research of other type III Evidences are originated from the well-designed non-interventional clinical researches, such as descriptive researches and relevant researches IV Evidences are originated from the reports made by committee of experts or the clinical reports of authoritative experts |
| Development unit： | Chinese Association of Liver Cancer and Chinese Medical Doctor Association |
| Registration time: | 2024-04-24 |
| Registration number： | PREPARE-2024CN583 |
| Purpose of the guideline: | At present, the international research on the diagnosis and treatment of hepatocellular carcinoma(HCC) complicated with bile duct tumor thrombus(BDTT) is few and no consensus has been reached. To provide the latest guiding suggestions for the standardized diagnosis and treatment of HCC with BDTT in China. In order to adapt to the development and changes of clinical diagnosis and treatment of HCC with BDTT, the Chinese Association of Liver Cancer of Chinese Medical Doctor Association issued the Guideline for diagnosis and treatment of hepatocellular carcinoma with bile duct tumor thrombus in China(2024) |
Latest registration
